US20150024070A1 - Ingestible canker sore treatment - Google Patents

Ingestible canker sore treatment Download PDF

Info

Publication number
US20150024070A1
US20150024070A1 US13/945,085 US201313945085A US2015024070A1 US 20150024070 A1 US20150024070 A1 US 20150024070A1 US 201313945085 A US201313945085 A US 201313945085A US 2015024070 A1 US2015024070 A1 US 2015024070A1
Authority
US
United States
Prior art keywords
ppm
vitamin
zinc
iron
vitamins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/945,085
Inventor
Plato Chun-Chih Lee
Arthur Joseph Dietrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/945,085 priority Critical patent/US20150024070A1/en
Priority to US14/047,442 priority patent/US8968796B2/en
Priority to PCT/US2014/046364 priority patent/WO2015009570A1/en
Priority to CA2918496A priority patent/CA2918496A1/en
Publication of US20150024070A1 publication Critical patent/US20150024070A1/en
Priority to US14/635,106 priority patent/US20150174165A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/592Mixtures of compounds complementing their respective functions
    • A61K2800/5922At least two compounds being classified in the same subclass of A61K8/18

Definitions

  • the present invention relates to canker sore treatment. More specifically, the invention relates to an ingestible canker sore treatment. Even more specifically, the invention relates to an ingestible spray for canker sore treatment.
  • a canker sore (medically known as a “aphthous ulcer”) is an ulceration of the inner mucosal membrane of the mouth, with occasional occurrence on the tongue and in the gum area. These ulcers cause discomfort at the very least, and often are a source of pain for afflicted persons, especially during eating and drinking. Individual sores typically last for one to two weeks, but recurrences can result in much longer afflictions. A large percentage of the population (approximately 20%-40%, depending on the survey) is known to have had at least one canker sore in their life and many have frequent recurrences of this painful medical condition.
  • canker sores are not well-known. Accordingly, there are no medications that can permanently cure or even prevent canker sores. Instead, there are a few commercial medications which merely treat the symptoms of canker sores. Most of these medications, both over the counter (OTC) and prescription medicines, are aimed at reducing the pain caused by canker sores, while others claim to “promote healing” by cleansing the affected area. However, none are capable of actually healing or even preventing the occurrence of canker sores. There is great need for a product that both inhibits the development of canker sores in all areas of the mouth, including the tongue and gums, at an early stage, and promotes healing of canker sores once they develop.
  • the present composition and application methods address these and other problems associated with canker sores. Where others have failed to appreciate the source of the problem or have overlooked the solution, the present composition prevents and heals canker sores while providing advantages in simplicity and effectiveness.
  • compositions for an ingestible canker sore treatment and a method for using the ingestible canker sore composition are disclosed.
  • the composition and treatment methods are effective in both prevention and treatment of canker sores within a user's oral cavity.
  • the composition is comprised of all natural ingredients, including at least three different B vitamins, zinc, and iron combined in an alkaline solution.
  • the different B vitamins include B 6 , B 9 and B 10 vitamins.
  • B 6 , B 9 and B 10 vitamins similar or additional B vitamins may be used for other applications.
  • the zinc component is preferably delivered using a chemical compound composed of a Zn (+2) cation and any suitable anion.
  • the iron component is preferably delivered using a chemical compound composed of a Fe (+2/+3) cation and any suitable anion.
  • the alkaline solution is preferably composed of any suitable alkali metal carbonate or hydroxide.
  • weight percentage of the specified components of the said solution are preferably about 3 parts-per-million (ppm) of Vitamin B 6 , 1 ppm of Vitamin B 9 , 1 ppm of Vitamin B 12 , 65 ppm of zinc, 56 ppm of iron, and 1200 ppm of carbonate.
  • Natural flavoring(s) of any suitable type may be added to the composition in an amount to make the treatment even more pleasant for the user.
  • the disclosed composition is provided in a spray bottle for dispersal into the user's oral cavity.
  • the composition may be provided in a capped bottle as a drinkable mouthwash. Alternate delivery methods are possible.
  • an ingestible medium of the composition disclosed is delivered to a user's oral cavity where it can be effectively moved to contact substantially the entirety of potentially afflicted areas for a suitable duration of time. Then, the ingestible treatment may be either dispelled from the mouth (i.e., spit out) or ingested.
  • the ingestible medium may be directed to an affected area only using a focused spray or the like. Again, the residual solution can then be expectorated or ingested.
  • canker sores Although the exact cause or causes for canker sores are not well-known, a large population has suffered from this potentially painful condition. The flair up of a canker sore can make it painful for a person to speak, drink, swallow or eat, depending the location and size of the canker sores. For many individuals, repeat occurrences are frequent and unpredictable.
  • the present formulation is directed to an ingestible mouth spray that aims at inhibiting the development of canker sores at an early stage and at healing existing canker sores should they develop.
  • the preferred composition is constituted of all natural chemical ingredients and is totally non-toxic.
  • the formulation includes the use of an alkaline solution as an effective treatment of canker sores.
  • the preferred formula also contains at least three B vitamins, zinc and iron, as deficiencies in these vitamins and minerals are commonly-known hosting factors of canker sores.
  • the B vitamins include vitamin B 6 , B 9 , and B 12 , but may include additional B vitamins.
  • a preferred embodiment of the formula contains the following chemical ingredients and measures (in parts-per-million (ppm)) in an aqueous solution:
  • the alkali metal is sodium (Na + ), but may also be potassium (K +), lithium (Li + ), or cesium (Cs + ).
  • the formula can be modified and the following ranges for the chemical ingredients are possible for alternate embodiments in an aqueous solution:
  • the composition Due to the non-toxicity of the composition, it can be applied to and held in the mouth as often and as long as the user prefers. This in turn allows longer contact between the mucosal membrane of the user's mouth and the composition. A user could allow an optimal time for an effective chemical reaction between the ingredients and the tissue, including any canker sores. Afterward, the composition can be swallowed. This provides a significant advantage over non-ingestible treatments, such as mouthwashes—i.e., it is not necessary to spit it out. The fact that this product is ingestible greatly enhances the timing that this product can be conveniently used or applied—the user can carry the product in his/her handbag or briefcase and use it almost anytime and almost anywhere. No longer does treatment require a bathroom sink or the like.
  • the product can be administered at the user's home while watching TV, at the user's office desk, in the airport without toting bags to the restroom, at the bus stop and on the bus, in a restaurant, and in an almost infinite number of other locations where it would be otherwise be inappropriate to dispel a mouthwash. More frequent and longer applications of the treatment leads to more effective prevention and treatment of canker sores.
  • the chemical composition results in a product which is neutral in both taste and smell.
  • the use of the composition is not offensive to others and significantly reduces the occasions for missing a treatment.
  • vitamin B 6 pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride
  • B 9 folic acid
  • B 12 variant cobalamins; commonly cyanocobalamin in vitamin supplements
  • zinc and iron have been added to the alkaline solution to improve the intake of these components and reduce the cause of canker sores due to the deficiencies in these components.
  • Other B vitamins such as B 1 (thiamine), B 2 (riboflavin), B 3 (niacin or niacinamide), B 5 (pantothenic acid) and B 7 (biotin; vitamin H) may be substituted or added to other formulations, if desired.
  • zinc in a preferred formulation is due to the fact that, in scientific literature, zinc has also been shown to be anti-ulceration and thus, will further help to reduce the likelihood of forming canker sores (ulceration of the mucous of the mouth).
  • An unhealed injury to any tissues are known to incite the inflammation reactions from the body.
  • trauma to the mouth also results in the inflammations and acidosis of the injured tissues in the mouth, resulting in the formation of canker sores.
  • canker sore sufferers avoid highly acidic food and drinks. This clinical advice correlates well with the fact that canker sores, irrespective of the causes, are in principle results of the inflammation and the ensuing acidosis of the mucous tissues and extracellular acidity from the drinks or foods will only exacerbate the inflammation.
  • the disclosed formulation therefore, directs to reverse the acidosis—and the possible ensuing ulcerations—of the mucous membranes of the mouth during early phases in the development of canker sores.
  • Such treatment as described, will result in prevention of and quicker healing of canker sores.
  • the preferred formulation is considered stable (for shelf-life consideration) and is a clear, non-toxic, all-natural, ingestible alkaline solution. It also has a pleasant taste, especially when a flavoring is included, and has no offensive odor to others.
  • the present embodiment can thus be applied in any work or social occasion without missing a dose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A treatment and prevention formulation for canker sores of the oral cavity including an aqueous alkaline solution having at least three B vitamins, zinc and iron mixed therein and administered to a target area by a spray container. The vitamins are B6, B9 and B12, but may include other vitamins as well. The formulation is all-natural, non-toxic and completely ingestible, so it may be used almost anywhere and at almost any time and can be swallowed after use.

Description

    TECHNICAL FIELD OF INVENTION
  • The present invention relates to canker sore treatment. More specifically, the invention relates to an ingestible canker sore treatment. Even more specifically, the invention relates to an ingestible spray for canker sore treatment.
  • BACKGROUND OF INVENTION
  • A canker sore (medically known as a “aphthous ulcer”) is an ulceration of the inner mucosal membrane of the mouth, with occasional occurrence on the tongue and in the gum area. These ulcers cause discomfort at the very least, and often are a source of pain for afflicted persons, especially during eating and drinking. Individual sores typically last for one to two weeks, but recurrences can result in much longer afflictions. A large percentage of the population (approximately 20%-40%, depending on the survey) is known to have had at least one canker sore in their life and many have frequent recurrences of this painful medical condition.
  • Currently, the cause or causes of canker sores are not well-known. Accordingly, there are no medications that can permanently cure or even prevent canker sores. Instead, there are a few commercial medications which merely treat the symptoms of canker sores. Most of these medications, both over the counter (OTC) and prescription medicines, are aimed at reducing the pain caused by canker sores, while others claim to “promote healing” by cleansing the affected area. However, none are capable of actually healing or even preventing the occurrence of canker sores. There is great need for a product that both inhibits the development of canker sores in all areas of the mouth, including the tongue and gums, at an early stage, and promotes healing of canker sores once they develop.
  • The present composition and application methods address these and other problems associated with canker sores. Where others have failed to appreciate the source of the problem or have overlooked the solution, the present composition prevents and heals canker sores while providing advantages in simplicity and effectiveness.
  • BRIEF SUMMARY OF THE INVENTION
  • A composition for an ingestible canker sore treatment and a method for using the ingestible canker sore composition are disclosed. The composition and treatment methods are effective in both prevention and treatment of canker sores within a user's oral cavity.
  • Generally speaking, the composition is comprised of all natural ingredients, including at least three different B vitamins, zinc, and iron combined in an alkaline solution.
  • In a particular embodiment of the composition, three of the different B vitamins include B6, B9 and B10 vitamins. However, similar or additional B vitamins may be used for other applications. Further, the zinc component is preferably delivered using a chemical compound composed of a Zn (+2) cation and any suitable anion. Similarly, the iron component is preferably delivered using a chemical compound composed of a Fe (+2/+3) cation and any suitable anion. The alkaline solution is preferably composed of any suitable alkali metal carbonate or hydroxide.
  • In particular embodiments of the composition, weight percentage of the specified components of the said solution are preferably about 3 parts-per-million (ppm) of Vitamin B6, 1 ppm of Vitamin B9, 1 ppm of Vitamin B12, 65 ppm of zinc, 56 ppm of iron, and 1200 ppm of carbonate.
  • Natural flavoring(s) of any suitable type may be added to the composition in an amount to make the treatment even more pleasant for the user.
  • In a particular embodiment, the disclosed composition is provided in a spray bottle for dispersal into the user's oral cavity. Alternatively, the composition may be provided in a capped bottle as a drinkable mouthwash. Alternate delivery methods are possible.
  • As to a method for relieving, treating and preventing canker sores in a user's oral cavity, an ingestible medium of the composition disclosed is delivered to a user's oral cavity where it can be effectively moved to contact substantially the entirety of potentially afflicted areas for a suitable duration of time. Then, the ingestible treatment may be either dispelled from the mouth (i.e., spit out) or ingested.
  • In an alternate method, the ingestible medium may be directed to an affected area only using a focused spray or the like. Again, the residual solution can then be expectorated or ingested.
  • Additional aspects and advantages of the disclosed invention can best be understood from a review of the following detailed description of the invention.
  • DETAILED DESCRIPTION OF THE INVENTION
  • While this invention is susceptible of embodiments in many different forms, there will herein be described in detail a preferred embodiment of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to any specific embodiments.
  • Although the exact cause or causes for canker sores are not well-known, a large population has suffered from this potentially painful condition. The flair up of a canker sore can make it painful for a person to speak, drink, swallow or eat, depending the location and size of the canker sores. For many individuals, repeat occurrences are frequent and unpredictable.
  • Various likely causes of canker sores have been proposed. A comparison of the more popular proposed causes points to a few commonly observed factors. One likely factor is a deficiency in the intake of vitamins, including B6, B9 and B12, and minerals, including zinc and iron. Another major factor that has been frequently cited as a cause of canker sores is stress. Still another cited factor for canker sore formation is trauma to the mouth, such as an accidental bite of the soft cheek tissue or the tongue. It is also believed that acidity can exacerbate the sores, which is why many medical professionals suggest canker sore sufferers avoid highly acidic food and drinks. While none of these factors alone may cause canker sores, the more factors present increases the likelihood of canker sore formation.
  • The present formulation is directed to an ingestible mouth spray that aims at inhibiting the development of canker sores at an early stage and at healing existing canker sores should they develop. The preferred composition is constituted of all natural chemical ingredients and is totally non-toxic.
  • Generally speaking, the formulation includes the use of an alkaline solution as an effective treatment of canker sores. The preferred formula also contains at least three B vitamins, zinc and iron, as deficiencies in these vitamins and minerals are commonly-known hosting factors of canker sores. Most preferably, the B vitamins include vitamin B6, B9, and B12, but may include additional B vitamins.
  • A preferred embodiment of the formula contains the following chemical ingredients and measures (in parts-per-million (ppm)) in an aqueous solution:
      • 1. an alkali metal carbonate: 1200 ppm [—CO3 (2−)]
      • 2. Vitamin B6: 3.0 ppm
      • 3. Vitamin B9: 1.0 ppm
      • 4. Vitamin B12: 1.0 ppm
      • 5. Zinc (II) Salt: 65 ppm in Zinc(II)
      • 6. Fe (II and/or III) Salt: 56 ppm in Fe(II and/or III)
      • 7. a natural flavoring chemical (such as grape): very minute amount, as needed
  • Preferably, the alkali metal is sodium (Na+), but may also be potassium (K+), lithium (Li +), or cesium (Cs+). Further, the formula can be modified and the following ranges for the chemical ingredients are possible for alternate embodiments in an aqueous solution:
  • 1. an alkali metal carbonate: 12 to 12000 ppm [—CO3 (2−)]
      • 2. an alkali metal hydroxide: 17 to 17000 ppm [OH−]
      • 3. Vitamin B6: 0.0 to 5.0 ppm
      • 4. Vitamin B9: 0.0 to 5.0 ppm
      • 5. Vitamin B12: 0.0 to 5.0 ppm
      • 6. Other B vitamins: 0.0 to 5.0 ppm
      • 7. Zinc (II) Salt: 0 to 100 ppm in Zinc(II)
      • 8. Fe (II and/or III) Salt: 0 to 80 ppm in Fe(II and/or III)
      • 9. natural flavoring chemical: 0.0 to as needed
  • Due to the non-toxicity of the composition, it can be applied to and held in the mouth as often and as long as the user prefers. This in turn allows longer contact between the mucosal membrane of the user's mouth and the composition. A user could allow an optimal time for an effective chemical reaction between the ingredients and the tissue, including any canker sores. Afterward, the composition can be swallowed. This provides a significant advantage over non-ingestible treatments, such as mouthwashes—i.e., it is not necessary to spit it out. The fact that this product is ingestible greatly enhances the timing that this product can be conveniently used or applied—the user can carry the product in his/her handbag or briefcase and use it almost anytime and almost anywhere. No longer does treatment require a bathroom sink or the like. The product can be administered at the user's home while watching TV, at the user's office desk, in the airport without toting bags to the restroom, at the bus stop and on the bus, in a restaurant, and in an almost infinite number of other locations where it would be otherwise be inappropriate to dispel a mouthwash. More frequent and longer applications of the treatment leads to more effective prevention and treatment of canker sores.
  • Further, the chemical composition results in a product which is neutral in both taste and smell. As such, the use of the composition, even in intimate social gatherings, is not offensive to others and significantly reduces the occasions for missing a treatment.
  • In a preferred formulation, vitamin B6 (pyridoxine, pyridoxal, or pyridoxamine, or pyridoxine hydrochloride), B9 (folic acid), B12 (various cobalamins; commonly cyanocobalamin in vitamin supplements), zinc and iron have been added to the alkaline solution to improve the intake of these components and reduce the cause of canker sores due to the deficiencies in these components. Other B vitamins, such as B1 (thiamine), B2 (riboflavin), B3 (niacin or niacinamide), B5 (pantothenic acid) and B7 (biotin; vitamin H) may be substituted or added to other formulations, if desired.
  • The inclusion of zinc in a preferred formulation is due to the fact that, in scientific literature, zinc has also been shown to be anti-ulceration and thus, will further help to reduce the likelihood of forming canker sores (ulceration of the mucous of the mouth).
  • Mental stress is believed to be a major and probably the most frequent contributing factor for the occurrence of canker sores. As much as stress is a psychological condition, it is however extremely import to realize that, this psychological condition does produce physiological changes. In 2012, Proceedings of National Academy of Sciences, USA, released a report that correlates stress and tissue inflammations. This strongly supports the long clinical observation that stress results in tissue inflammation. Inflammation biochemically results in acidosis of the body's tissues. There have been many studies which support the fact that under stress, many tissues/organs are more acidic than those of a control group. The ulcerations of the tissues come as a result of the prolonged stress and prolonged acidosis of the tissues, such as the mucous membranes of the mouth.
  • Trauma to the mouth, such as an accidental bite of the soft cheek or the tongue is believed to be another factor for the occurrence of canker sores. An unhealed injury to any tissues are known to incite the inflammation reactions from the body. Thus, just like mental stress, trauma to the mouth also results in the inflammations and acidosis of the injured tissues in the mouth, resulting in the formation of canker sores.
  • Many medical professionals suggest canker sore sufferers avoid highly acidic food and drinks. This clinical advice correlates well with the fact that canker sores, irrespective of the causes, are in principle results of the inflammation and the ensuing acidosis of the mucous tissues and extracellular acidity from the drinks or foods will only exacerbate the inflammation.
  • The disclosed formulation, therefore, directs to reverse the acidosis—and the possible ensuing ulcerations—of the mucous membranes of the mouth during early phases in the development of canker sores. Such treatment, as described, will result in prevention of and quicker healing of canker sores.
  • The preferred formulation is considered stable (for shelf-life consideration) and is a clear, non-toxic, all-natural, ingestible alkaline solution. It also has a pleasant taste, especially when a flavoring is included, and has no offensive odor to others. The present embodiment can thus be applied in any work or social occasion without missing a dose.
  • The matter set forth in the foregoing description is offered by way of illustration only and not as a limitation. While particular embodiments have been described, it will be apparent to those skilled in the art that changes and modifications may be made without departing from the broader aspects of applicants' contribution. The actual scope of the protection sought is intended to be defined in the following claims when viewed in their proper perspective based on relevant prior art.

Claims (25)

What is claim is:
1. An ingestible formulation for the treatment and prevention of canker sores, the formula consisting essentially of:
at least three B vitamins;
zinc;
iron; and
an alkaline solution, wherein the B vitamins, zinc and iron are mixed in the solution.
2. The ingestible formulation of claim 1, wherein the at least three B vitamins comprise vitamin B6, vitamin B9 and vitamin B12.
3. The ingestible formulation of claim 1, wherein zinc is provided by a chemical compound composed of Zn(2+) and a suitable anion.
4. The ingestible formulation of claim 1, wherein the iron is provided by a chemical compound composed of at least one of either Fe(2+) and Fe (3+) and a suitable anion.
5. The ingestible formulation of claim 1, wherein the alkaline solution comprises a suitable alkali metal hydroxide in an amount in the range of 200 to 500 ppm.
6. The ingestible formulation of claim 1, wherein the alkaline solution comprises a suitable alkali metal carbonate.
7. The ingestible formulation of claim 5, wherein the alkali metal hydroxide is sodium hydroxide.
8. The ingestible formulation of claim 6, wherein the alkali metal carbonate is sodium carbonate.
9. The ingestible formulation of claim 6, wherein the amount of each component is within the following ranges:
alkali metal carbonate: 800 to 1500 ppm;
vitamin B6: 0.0 to 5.0 ppm;
vitamin B9: 0.0 to 5.0 ppm;
vitamin B12: 0.0 to 5.0 ppm;
zinc as zinc (II): 0 to 100 ppm; and
iron as at least one of either Fe (II) and Fe (III): 0 to 80 ppm.
10. The ingestible formulation of claim 9, further comprising additional B vitamins in the range of from about 0.1 ppm to about 5.0 ppm.
11. The ingestible formulation of claim 9, further comprising a natural flavoring chemical.
12. A combination all-natural chemical treatment and applicator for preventing and treating canker sores in the oral cavity of a user, the combination comprising:
a spray container capable of dispensing a measured amount of solution;
an aqueous alkaline solution stored within the spray container, the solution comprising:
at least three B vitamins;
zinc; and
iron.
13. The combination of claim 12, wherein the at least three B vitamins comprise vitamin B6, vitamin B9 and vitamin B12.
14. The combination of claim 12, wherein zinc is provided by a chemical compound composed of Zn(2+) and a suitable anion.
15. The combination of claim 12, wherein the iron is provided by a chemical compound composed of at least one of either Fe(+2) and Fe(3+) and a suitable anion.
16. The combination of claim 12, wherein the alkaline solution comprises a suitable alkali metal carbonate.
17. The combination of claim 16, wherein the amount of each component of the solution is within the following ranges:
alkali metal carbonate: 800 to 1500 ppm;
vitamin B6: 0.0 to 5.0 ppm;
vitamin B9: 0.0 to 5.0 ppm;
vitamin B12: 0.0 to 5.0 ppm;
zinc as zinc (II): 0 to 100 ppm; and
iron as at least one of either Fe (II) and Fe (III): 0 to 80 ppm.
18. A method for one of either treatment or prevention of canker sores comprising the steps of:
administering to a target area an aqueous solution having the following composition:
at least three B vitamins;
zinc;
iron; and
water;
allowing the aqueous solution to maintain contact with the target area for a period of time; and
removing the aqueous solution from the target area after the period of time.
19. The method of claim 18, wherein the step of removing comprises the step of swallowing the aqueous solution.
20. The method of claim 18, wherein the at least three B vitamins comprise vitamin B6, vitamin B9 and vitamin B12.
21. The method of claim 20, wherein zinc is provided by a chemical compound composed of Zn(2+) and a suitable anion.
22. The method of claim 21, wherein the iron is provided by a chemical compound composed of at least one of either Fe(+2) and Fe(3+) and a suitable anion.
23. The method of claim 22, wherein the alkaline solution comprises a suitable alkali metal carbonate.
24. The method of claim 23, wherein the amount of each component of the aqueous solution is within the following ranges:
alkali metal carbonate: 800 to 1500 ppm;
vitamin B6: 0.0 to 5.0 ppm;
vitamin B9: 0.0 to 5.0 ppm;
vitamin B12: 0.0 to 5.0 ppm;
zinc as zinc (II): 0 to 100 ppm; and
iron as Fe (II and/or III): 0 to 80 ppm.
25. The method of claim 18, wherein the step of administering comprising the step of spraying the aqueous solution on the target area.
US13/945,085 2013-07-18 2013-07-18 Ingestible canker sore treatment Abandoned US20150024070A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US13/945,085 US20150024070A1 (en) 2013-07-18 2013-07-18 Ingestible canker sore treatment
US14/047,442 US8968796B2 (en) 2013-07-18 2013-10-07 Ingestible canker sore treatment
PCT/US2014/046364 WO2015009570A1 (en) 2013-07-18 2014-07-11 Ingestible canker sore treatment
CA2918496A CA2918496A1 (en) 2013-07-18 2014-07-11 Ingestible canker sore treatment
US14/635,106 US20150174165A1 (en) 2013-07-18 2015-03-02 Ingestible canker sore treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/945,085 US20150024070A1 (en) 2013-07-18 2013-07-18 Ingestible canker sore treatment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/047,442 Continuation US8968796B2 (en) 2013-07-18 2013-10-07 Ingestible canker sore treatment
US14/047,442 Continuation-In-Part US8968796B2 (en) 2013-07-18 2013-10-07 Ingestible canker sore treatment

Publications (1)

Publication Number Publication Date
US20150024070A1 true US20150024070A1 (en) 2015-01-22

Family

ID=52343759

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/945,085 Abandoned US20150024070A1 (en) 2013-07-18 2013-07-18 Ingestible canker sore treatment
US14/047,442 Expired - Fee Related US8968796B2 (en) 2013-07-18 2013-10-07 Ingestible canker sore treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/047,442 Expired - Fee Related US8968796B2 (en) 2013-07-18 2013-10-07 Ingestible canker sore treatment

Country Status (3)

Country Link
US (2) US20150024070A1 (en)
CA (1) CA2918496A1 (en)
WO (1) WO2015009570A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190032622A1 (en) * 2016-02-05 2019-01-31 Nissan Motor Co., Ltd. Control method and control device for internal combustion engine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028311A (en) * 1990-04-12 1991-07-02 Conoco Inc. Delayed coking process
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US20020061347A1 (en) * 1995-10-27 2002-05-23 The Procter & Gamble Co. Color stable iron fortified compositions
US20060093705A1 (en) * 2002-09-19 2006-05-04 Haile Mehansho Mineral fortified water
US20060134020A1 (en) * 2004-12-21 2006-06-22 Robinson Richard S Anti-caries oral care composition with a chelating agent
US20100143554A1 (en) * 2007-05-08 2010-06-10 Kao Corporation Concentrate composition for drink from concentrate
US20110135786A1 (en) * 2007-10-26 2011-06-09 The Hershey Company Cocoa-based exercise recovery beverages

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8410290D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
CA2071837C (en) 1990-10-16 2001-01-02 Joseph A. Deihl Vitamin-mineral treatment methods and compositions
CA2211382A1 (en) 1996-07-26 1998-01-26 Dental Research Laboratories, Inc. Method for maintenance and preservation of dental health and oral dental health dietary supplement for use in said method
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US20050058671A1 (en) 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
JP2005068060A (en) * 2003-08-22 2005-03-17 Nrl Pharma Inc Pharmaceutical composition containing lactoferrin and method for producing processed food containing lactoferrin
EP1690457B1 (en) * 2003-12-02 2010-08-11 Kao Corporation Package drink
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20050208119A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Encapsulated oral chelating preparations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028311A (en) * 1990-04-12 1991-07-02 Conoco Inc. Delayed coking process
US20020061347A1 (en) * 1995-10-27 2002-05-23 The Procter & Gamble Co. Color stable iron fortified compositions
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US20060093705A1 (en) * 2002-09-19 2006-05-04 Haile Mehansho Mineral fortified water
US20060134020A1 (en) * 2004-12-21 2006-06-22 Robinson Richard S Anti-caries oral care composition with a chelating agent
US20100143554A1 (en) * 2007-05-08 2010-06-10 Kao Corporation Concentrate composition for drink from concentrate
US20110135786A1 (en) * 2007-10-26 2011-06-09 The Hershey Company Cocoa-based exercise recovery beverages

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lenntech BV, "Recommended Daily Intake of Vitamins and Minerals", pg. 1-2, 06/14/2012. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190032622A1 (en) * 2016-02-05 2019-01-31 Nissan Motor Co., Ltd. Control method and control device for internal combustion engine

Also Published As

Publication number Publication date
CA2918496A1 (en) 2015-01-22
US20150024067A1 (en) 2015-01-22
WO2015009570A1 (en) 2015-01-22
US8968796B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
US6407141B1 (en) Oxalic acid or oxalate compositions and methods for vascular disorders, diseases, and calcerous conditions
US20220016246A1 (en) Hypertonic antimicrobial therapeutic compositions
US20080044455A1 (en) Tonsillitus Treatment
JP2002507548A (en) Xylitol formulation for treating upper airway conditions
RU2570754C2 (en) Combination for radiation- or chemotherapy-induced mucositis
US9795633B2 (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne
RU2757379C2 (en) Composition for the treatment of veisalgia
AU2014318702A1 (en) Hypertonic antimicrobial therapeutic compositions
TW200524585A (en) Human β-defensin secretion promoter
RU2762754C2 (en) Composition applicable in prevention and/or treatment of oral and gastrointestinal mucositis induced by oncological treatment
US20170080024A1 (en) Effervescent gargle tablet and method of using same
Subiksha Various remedies for recurrent aphthous ulcer-a review
CN106176315B (en) A kind of mouthwash and preparation method thereof
US8968796B2 (en) Ingestible canker sore treatment
US20040082667A1 (en) Hangover treatment
US20150174165A1 (en) Ingestible canker sore treatment
US10493302B2 (en) Compositions for human dental care
WO2009031922A1 (en) Tablet for prophylaxis and treatment of dental and periodontium diseases
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
US20140356449A1 (en) Sore throat remedy
US20120107419A1 (en) Oral rinse formulation and method of use
US20040192587A9 (en) Zinc formulations as a prophylactic treatment for the common cold
US9539228B2 (en) Composition containing lysine as a nutritional supplement or treatment in the case of herpes
CN113181313A (en) Herbal pregnancy-arresting pill
Setiawan et al. Comparative effects of chlorhexidine gluconate and povidone iodine mouthwashes to chemotherapy-induced oral mucositis in children with acute lymphoblastic leukemia

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION